Skip to Content

Nicox SA Share from reverse split NICXF Stock Quote

| Rating as of


Market Closed

Chart Data Not Available

No price data available

  • Last Close 0.64
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 0.64  –  0.64
  • Year Range 0.64  –  1.85
  • Market Cap 31.9097 Mil
  • Volume / Avg 1,010.0 /  769.0
  • Price / Sales 5.08
  • Price / Book 0.57
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis NICXF

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics NICXF

Company Profile NICXF

Business Description

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne
Sophia Antipolis, 06560, FRA
Industry Biotechnology
Employees 28

Competitors & Peers NICXF

Morningstar does not cover competitors or peers for this firm.

FAQs for Nicox SA Share from reverse split Stock

No. NICXF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

NICXF’s market cap is 31.91 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

NICXF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

NICXF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare NICXF’s historical performance against its industry peers and the overall market.